ANGLE is a world-leading liquid biopsy company with offices in Guildford (UK), Toronto (Canada) and Greater Philadelphia (USA). ANGLE’s patented liquid biopsy platform Parsortix® PC1 Clinical System is the first FDA cleared medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis. The ability to monitor and analyse CTCs may transform the treatment of MBC, providing patients with personalized cancer care through a non-invasive, repeat liquid biopsy with the power of Parsortix® technology. ANGLE has two GCP-compliant clinical service laboratories based out of the US and the UK. Our clinical laboratories employ standardized workflows for analysis of epithelial and mesenchymal CTCs and have the capability to develop custom CTC assays. These assays have the potential to provide clinicians with individualized, up-to-date, and clinically actionable insight into a patient’s cancer, and may improve clinical outcomes for those individuals as a result.